Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

HLX10 : A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Multiple<Br/>Treatment TypesTypeMultiple
Treatment Types

ThreePhase Three

18+Age Over 18

Lung<br/>CancersCancer LocationLung
Cancers

Multiple treatment types,Radiotherapy,Systemic therapy | LungSmall Cell Lung Cancer

Trial Overview Read MoreRead more

This study is comparing the effectiveness of chemotherapy and radiation therapy when given with or without a new targeted therapy (HLX10) in people with limited-stage small cell lung cancer.
 

This trial is treating patients with small cell lung cancer.

This is a systemic therapy and radiation therapy trial.

You may be excluded from this trial if:

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Commercial Sponsor

Shanghai Henlius Biotech

Summary

Eligible participants will be randomly allocated to either the Experimental Arm or the Placebo Comparator Arm. All participants will receive active treatment. In the Experimental Arm, participants will receive 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) plus HLX10 (300mg) every three weeks, at the same time as receiving standard thoracic radiation therapy. In the Placebo Comparator Arm, participants will receive 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) plus a placebo every 3 weeks, at the same time as receiving thoracic radiation therapy.

Recruiting Hospitals Read MoreRead more

Monash Health, Medical Oncology
Clayton
Lung and Head & Neck Research Study Coordinator
lung.oncresearch@monashhealth.org
0417607146

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next